VAGA Helps People Suffering with Poor Mental Health or Cognitive Decline Through Art Therapy
13 juin 2022 09h00 HE
|
Vaga
New York, June 13, 2022 (GLOBE NEWSWIRE) -- Mental health is a topic that has been under the spotlight in recent years, as people are realising that it is just as important as physical health and...
Behavioral Health Market to Cross Valuation of US$ 262 Bn by 2031; Growing Need for Treating Substance Abuse Disorders Underpins Abundant Avenues: TMR Study
06 juin 2022 12h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, June 06, 2022 (GLOBE NEWSWIRE) -- The global market study on behavioral health market is witnessing steady creation of lucrative opportunities on the back of...
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
04 mai 2022 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Insights on the Mental Health Apps Global Market to 2027: Featuring Sanvello Health, Flow Neuroscience and Youper Among Others
21 avr. 2022 05h08 HE
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Global Mental Health Apps Market Size, Share & Industry Trends Analysis Report By Application, By Platform Type (iOS, Android, and Others), By...
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
07 avr. 2022 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS)...
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
28 févr. 2022 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
09 nov. 2021 07h00 HE
|
Zai Lab Limited; Karuna Therapeutics
Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to receive upfront cash payment of $35 million, up to $152 million in potential near- and long-term...
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates
08 nov. 2021 07h30 HE
|
Minerva Neurosciences, Inc
Company to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
01 nov. 2021 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Promotion of Geoff Race to President
11 oct. 2021 08h30 HE
|
Minerva Neurosciences, Inc
Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc....